Table 1

Factors affecting performance of tuberculosis screening tests

Author-year/countryPatients (N)DiseaseAssociation with TSTRoB
BCGGCcsDMARDs
Ruan et al17 2016/NA*1940AΙΙRDPositive
OR: 1.64 (95% CI 1.06 to 2.53)
Negative
OR 0.45 (95% CI 0.30 to 0.69)
High quality
Reitblat et al24 2018/Israel65RANoNo7
Agarwal et al23 2014/USA250RANegative
(mean dose†: 6.4), (p=0.002)
No7
Hsia et al13 2012/multinational2303IAPositive
(p<0.0002 vs IGRA)
7
Klein et al18 2013/Czech305AIIRDNegative, (p=0.0172)Negative (combination with GC) (p=0.0003)6
Belard et al 22 2011/Denmark248AIIRD‡Negative (p=0.018)6
Soborg et al20 2009/Denmark302IANegative
RR 0.4 (95% CI 0.1 to 1.0), (p=0.04)
6
Tamborenea et al21 2009/Argentina105RANegative (mean dose: 6 mg/day),
OR 0.72 (95% CI 0.55 to 0.95), p=0.021
6
Vassilopoulos et al15 2008/Greece70AIIRDPositive§Negative (mean dose: 6.8 mg)¶6
Arias-Guillen et al26 2018/Spain393IAPositive (MTX)
OR 2.15 (95% CI 1.05 to 4.44)
5
Maeda et al14 2011/Japan97RAPositive
(14/19 false-positive TST)
5
Sargin et al25 2018/Turkey109IANo4
Lee et al16 2012/South Korea81RANo4
Lee et al16 2012/South Korea81RANoNo4
Author-year/countryPatients (N)DiseaseAssociation** with IGRARoB
Ruan et al17 2016/NA1940AIIRDNo (GC, csDMARDs)High quality
Vassilopoulos et al55 2011/Greece155AIIRDNegative (GC, mean GC dose: 6.8 mg), (OR=0.31 95% CI 0.1 to 0.96; p=0.04)6
Belard 2011 et al22 /Dennmark248AIIRD‡With indeterminate IGRA (GC), OR=6.1 95% CI 4.1 to 63.2; p<0.001)6
Soborg et al20 2009/Denmark302IAWith indeterminate IGRA (GC), RR 4.2 (95% CI 1.6 to 10.7, p=0.04)6
Arias-Guillen et al26 2018/Spain393IANo (MTX)5
Maeda et al14 2011/Japan97RANo (GC, (mean dose prednisolone: 5.7 mg), MTX)5
Shovman et al31 2009/Israel35RANo (GC, (mean dose prednisolone: 8.3 mg), MTX)5
Matulis et al30 2008/UK142IMIDNo (GC, csDMARDs)5
  • *Meta-analysis.

  • †GC dose: prednisolone or equivalent.

  • ‡93/244 patients had inflammatory bowel disease.

  • §BCG associated with TST-positive/IGRA-negative discordant status (p=0.01).

  • ¶Associated with TST-negative/IGRA-positive discordant status (p=0.04).

  • **Association of GC or csDMARDs with IGRA.

  • AIIRD, autoimmune inflammatory rheumatic disease; csDMARDs, conventional synthetic DMARD; DMARDs, disease modifying anti-rheumatic drugs; GC, glucocorticoids; IA, inflammatory arthritis; IGRA, interferon releasee gamma assay; IMID, immune mediated disease; MTX, methotrexate; NA, not available; RA, rheumatoid arthritis; RoB, risk of bias; RR, risk ratio; TST, tuberculin skin test.